
Aficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.
The Q3 recap for cardiology spotlights major FDA decisions, new heart failure and hypertension guidelines, and top trial results and research.
The third quarter of 2025 saw a series of revolutionary changes in cardiology, with major regulatory updates, significant new trail data, and the release of new guidelines in






